Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients
Summary of the effects of iDegLira and iGlarLixi on postprandial... | Download Scientific Diagram
US approval for Novo Nordisk's Xultophy/IDegLira as diabetes battle hots up
Peter Falck Christens, Manager Biostatistics IdegLira, (Novo Nordisk) — Ministry of Music
Switching to a fixed-ratio combination of insulin degludec/liraglutide ( IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Novel insulin/GLP-1 combo succeeds in phase III trial | MDedge Endocrinology
ADA 2014: New data on Novo Nordisk's IDegLira and Victoza
Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in
Ideglira (Novo Nordisk) | Bioz | Ratings For Life-Science Research
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes
Novo Nordisk debuts diabetes combo in Mexico - PMLiVE
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes | Drugs
Positive Phase 3b study resutls for Xultophy announced
Overview of studies design evaluating the efficacy of iDegLira and... | Download Scientific Diagram
Novo posts strong performance, but US pricing pressure grows | pharmaphorum
In a showdown with Sanofi, FDA questions Novo's PhIII data for IDegLira | Fierce Biotech
REMIT-iDegLira - Research Studies - PHRI - Population Health Research Institute of Canada
